The role of 11C-Choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL

Clinical Nuclear Medicine

Volumn 38, Issue 9, 2013, Pages

  Mamede, Marcelo ^a,b   Ceci, Francesco ^a   Castellucci, Paolo ^a   Schiavina, Riccardo ^a   Fuccio, Chiara ^c   Nanni, Cristina ^a   Brunocilla, Eugenio ^a   Fantini, Lorenzo ^a   Costa, Stefano ^a   Ferretti, Alice ^d   Colletti, Patrick M ^e   Rubello, Domenico ^d   Fanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c IRCCS   (Italy)

^d SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

11C choline; molecular imaging; PET CT; prostate cancer

Indexed keywords

CHOLINE C 11; PROSTATE SPECIFIC ANTIGEN; CARBON; CHOLINE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CHOLINE UPTAKE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISTANT METASTASIS; EARLY DIAGNOSIS; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; METABOLISM; MIDDLE AGED; MULTIMODAL IMAGING; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; POSITRON EMISSION TOMOGRAPHY; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOGRAPHY; SCINTISCANNING; STATISTICAL MODEL; PROSTATE TUMOR; TUMOR RECURRENCE;

CARBON RADIOISOTOPES; CHOLINE; EARLY DETECTION OF CANCER; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84883319165     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31829af913     Document Type: Article

References (21)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69Y90.
2. Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517Y523.
3. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59:572Y583.
4. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61Y71.
5. Coakley FV, Teh HS, Qayyum A, et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology. 2004;233:441Y448.
6. Choueiri TK, Dreicer R, Paciorek A, et al. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol. 2008;179:906Y910.
7. Cirillo S, Petracchini M, Scotti L, et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol. 2009;19: 761Y769.
8. Muller SA, Holzapfel K, Seidl C, et al. Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment. Eur J Nucl Med Mol Imaging. 2009;36:1434Y1442.
9. Krause BJ, Souvatzoglou M, Tuncel M, et al. The detection rate of [11C] choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:18Y23.
10. Castellucci P, Fuccio C, Nanni C, et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50:1394Y1400.
11. Marzola MC, Chondrogiannis S, Ferretti A, et al. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution. Clin Nucl Med. 2013;38:e26Ye32.
12. Castellucci P, Fuccio C, Rubello D, et al. Is there a role for 11C-choline PET/ CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase G1.5 ng/ml? Eur J Nucl Med Mol Imaging. 2011;38:55Y63.
13. Pascali C, Bogni A, Iwata R. 11C-methylation on 18C SepPak cartridge: a convenient way to produce [N-methyl-11C] choline. J Labelled Compds Radiopharm. 2000;49:195Y203.
14. Khan MA, Carter HB, Epstein JI, et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol. 2003;170:2274Y2278.
15. Svatek RS, Shulman M, Choudary PK, et al. Critical analysis of prostatespecific antigen doubling time calculation methodology. Cancer. 2006;106: 1047Y1053.
16. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancerspecific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433Y439.
17. Evangelista L, Zattoni F, Guttilla A, et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med. 2013;38:305Y314.
18. Souvatzoglou M, Krause BJ, Purschel A, et al. Influence of (11)C-choline on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol. 2011;99:193Y200.
19. Picchio M, Giovannini E, Crivellaro C, et al. Clinical evidence on PET/CT for radiation therapy planning in prostate cancer. Radiother Oncol. 2010;96:347Y350.
20. Ceci F, Castellucci P, Mamede M, et al. (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2013;40:149Y155.
21. Ceci F, Schiavina F, Castellucci P, et al. 11C-Choline PET/CT scan in patients with prostate cancer treated with intermittent ADT: a sequential PET/CT study. Clin Nucl Med. 2013;38:e279Ye282. pag e346-e353